THELMA Therapeutics Co., Ltd. announced a private placement of series 53 bearer type non-guaranteed private placement convertible bonds for a gross proceeds of KRW 2,000,000,000 on December 16, 2021. The transaction will include participation from Seocho Investment Association No.2. The bonds do not bear any interest rate and maturity rate and will mature on January 17, 2025. The bonds are convertible into 1,176,470 common shares at a fixed conversion price of KRW 1,700 per share and the conversion period is from January 17, 2023 to December 17, 2024.

The transaction has been approved by board of directors of the company and is expected to close on January 17, 2022.